R&D Pipeline

Nektar Therapeutics has a deep and diverse portfolio of investigational medicines in different stages of clinical development. We are focused on using new chemistry approaches to make better medicines to treat cancer and auto-immune disease.

Nektar Therapeutics also has a number of strategic partnerships ranging from joint discovery and co-development to licensing and royalty arrangements with numerous companies.

Bempegaldesleukin in combination with OPDIVO® (nivolumab)

Indication: Muscle-invasive Bladder Cancer

Partner
Partner

Phase 3

Bempegaldesleukin in combination with OPDIVO® (nivolumab)

Indication: Urothelial Cancer*

Partner
Partner

Phase 2

Bempegaldesleukin in combination with OPDIVO® (nivolumab)

Research Focus: Immuno-oncology

Discovered by Nektar

In clinical collaboration with Collaborator

Phase 2

Dapirolizumab Pegol (Anti-CD40L)

Indication: Systemic lupus erythematosus (SLE)

Partner
Partner

In partnership with Partner

Phase 2

Systemic lupus erythematosus (SLE) is a chronic inflammatory disease that occurs when the body's own immune system mistakenly attacks healthy tissue in skin, joints, kidneys, the brain and other organs. It is a difficult disease to diagnose because it resembles several other conditions.

CD40L is a protein in B and T cells, which helps regulate the immune system. Dapirolizumab pegol (Anti-CD40L) is an antibody that blocks CD40L, potentially lessening disease activity in SLE patients. Dapirolizumab pegol is being developed by Biogen and UCB, Inc. in a Phase 2 clinical trial to evaluate the efficacy and safety of dapirolizumab pegol in patients with moderately to severely active systemic lupus erythematosus. For more information about this study, visit clinicaltrials.gov.

Bempegaldesleukin in combination with VB10.NEO

Indication: Squamous Cell Carcinoma of the Head and Neck

In clinical collaboration with Collaborator

Phase 1/2A

Bempegaldesleukin in combination with avelumab

Indication: Squamous Cell Carcinoma of the Head and Neck

In clinical collaboration with Collaborator

Phase 1b

Bempegaldesleukin in combination with avelumab and talazaparib or enzalutamide

Indication: Metastatic Castration-resistant Prostate Cancer

In clinical collaboration with Collaborator

Phase 1b

NKTR-358

INDICATION: Systemic Lupus Erythematosus

Discovered by Nektar

Partner
Partner

Phase 1B

NKTR-358

INDICATION: Psoriasis

Discovered by Nektar

Partner
Partner

Phase 1B

NKTR-358

INDICATION: Atopic Dermatitis

Discovered by Nektar

Partner
Partner

Phase 1B

Bempegaldesleukin in combination with KEYTRUDA® (pembrolizumab)

Indication: Select Advanced or Metastatic Solid Tumors

Discovered and wholly owned by Nektar

Unpartnered

Phase 1

NKTR-262 in combination with bempegaldesleukin

INDICATION: Locally Advanced or Metastatic Solid Tumor Malignancies

Discovered and wholly owned by Nektar

Unpartnered

Phase 1

NKTR-255

INDICATION: Hematological Malignancies

Discovered and wholly owned by Nektar

Unpartnered

Phase 1

NKTR-255 is a memory T cell stimulating cytokine designed to engage the IL-15 pathway to enhance and sustain long-term T cell memory response to treat cancer.

*Planned registrational study